Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

(2013) D. Furst et al.   BLOOD

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

(2013) S. Bringhen et al.   HAEMATOLOGICA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

(2012) A. Palumbo et al.   HAEMATOLOGICA

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

(2011) P. M. Fayers et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

(2011) G. J. Morgan et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

(2009) Martin Kropff et al.   ANNALS OF HEMATOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE